Kiniksa Pharmaceuticals International, plc (KNSA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 39 | 220 | 270 | 423 | 678 | 841 | 994 |
| Operating profit | $m | 77 | 100 | ||||||
| Net profit | $m | -161 | -158 | 183 | 14 | -43 | 59 | 81 | 101 |
| EPS reported | $ | 0.75 | 0.98 | ||||||
| Operating cashflow per share | $ | 0.35 | 2.39 | ||||||
| Capex per share | $ | 0.00 | 0.03 | ||||||
| FCF per share | $ | 0.34 | 2.36 | ||||||
| Free cash flow | $m | 25 | 183 | ||||||
| Net debt | $m | -411 | -526 | ||||||
| Book value equity | $m | 568 | 654 | ||||||
| Book value per share | $ | 7.19 | 7.84 | ||||||
| Number of shares | m | 78.98 | 83.4 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 55.00 | 76.61 | ||||||
| P/B LTM | x | 5.39 | 4.68 | ||||||
| P/S LTM | x | 4.52 | 3.64 | ||||||
| P/FCF LTM | x | 120.45 | 16.72 | ||||||
| EV/EBITDA LTM | x | 32.12 | 25.91 | ||||||
| EV/Sales LTM | x | 4.29 | 6.76 | ||||||
| Earnings Yield LTM | % | +1.82% | +1.31% | ||||||
| FCF Yield | % | +0.83% | +5.98% | ||||||
| Quality | |||||||||
| ROE | % | +10.40% | +13.65% | ||||||
| ROIC | % | +8.17% | +9.71% | ||||||
| Operating margin | % | +11.40% | +11.92% | ||||||
| Gross margin | % | +54.63% | +54.49% | ||||||
| FCF/Sales | % | +3.75% | +21.78% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +60.09% | +98.67% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | 0.00% | +620.53% | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 2.68 | 20.58 | ||||||
| Net Debt/EBITDA | x | -1.73 | -1.49 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.10% | 0.00% | ||||||
| Net debt/Equity | x | -0.72 | -0.80 | ||||||
| Gross debt/equity | x | 0.02 | 0.01 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Kiniksa Pharmaceuticals International, plc (KNSA)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free